Modalis Therapeutics Corporation Logo

Modalis Therapeutics Corporation

Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.

4883 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
中央区日本橋本町三丁目11番5号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Modalis Therapeutics Corporation is a biotechnology company that pioneers the development of therapeutics for genetic diseases through epigenome editing. The company's proprietary core platform, CRISPR-GNDM®, is an advanced technology designed to regulate gene expression by selectively activating or suppressing specific genes without altering the underlying DNA sequence. This system utilizes a compact editor that can be delivered to target cells via AAV vectors. Modalis operates a hybrid business model, advancing therapeutic candidates through both in-house development pipelines for subsequent licensing and collaborative partnerships. Its development pipeline is focused on addressing unmet medical needs in muscular disorders, cardiomyopathy, and central nervous system (CNS) disorders.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Modalis Therapeutics Corporation and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-14 08:48
Regulatory News Service
訂正有価証券届出書(組込方式)
Japanese 237.5 KB
2025-08-14 08:31
Regulatory News Service
確認書
Japanese 8.9 KB
2025-08-14 08:30
Interim Report
半期報告書-第10期(2025/01/01-2025/12/31)
Japanese 266.6 KB
2025-08-07 08:32
Prospectus
有価証券届出書(組込方式)
Japanese 334.6 KB
2025-03-28 07:52
Regulatory News Service
臨時報告書
Japanese 28.4 KB
2025-03-27 08:32
Regulatory News Service
内部統制報告書-第9期(2024/01/01-2024/12/31)
Japanese 24.1 KB
2025-03-27 08:30
Regulatory News Service
確認書
Japanese 8.7 KB
2025-03-27 08:29
Annual Report
有価証券報告書-第9期(2024/01/01-2024/12/31)
Japanese 2.1 MB
2025-02-21 07:31
Regulatory News Service
臨時報告書
Japanese 21.5 KB
2024-08-13 08:14
Regulatory News Service
訂正有価証券届出書(組込方式)
Japanese 293.9 KB
2024-08-13 07:58
Interim Report
半期報告書-第9期(2024/01/01-2024/12/31)
Japanese 249.6 KB
2024-08-13 07:58
Regulatory News Service
確認書
Japanese 8.9 KB
2024-08-07 08:01
Prospectus
有価証券届出書(組込方式)
Japanese 495.2 KB
2024-05-14 06:00
Quarterly Report
四半期報告書-第9期第1四半期(2024/01/01-2024/03/31)
Japanese 166.1 KB
2024-05-14 06:00
Regulatory News Service
確認書
Japanese 8.9 KB

Automate Your Workflow. Get a real-time feed of all Modalis Therapeutics Corporation filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Modalis Therapeutics Corporation via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
NANO MRNA Co.,Ltd. Logo
Biotech IP generator developing and licensing mRNA therapeutics using proprietary delivery systems.
Japan 4571
NATURECELL CO.,LTD. Logo
Biotech company developing stem cell therapies, food, beverages, and cosmetics.
South Korea 007390
A marketing support firm using a vast consumer panel for data-driven research and PR campaigns.
Japan 4196
Neovacs Logo
Develops immunotherapy vaccines for autoimmune diseases & invests in BioTech/MedTech companies.
France ALNEV
Mineral explorer of rare earths, niobium, uranium, and copper assets in Australia and Zambia.
Australia N/A
NFL Biosciences Logo
Develops botanical drug candidates to treat smoking and alcohol addictions.
France ALNFL
NGS Group Logo
Nordic staffing & recruitment for healthcare, education, and social services sectors.
Sweden NGS
Nihon M&A Center Holdings Inc. Logo
M&A advisory firm specializing in brokerage and consulting for Japanese SMEs, including cross-border deals.
Japan 2127
Noile-Immune Biotech Inc. Logo
Developing PRIME technology-enhanced CAR-T cell immunotherapies for treating solid tumors.
Japan 4893
NRGene Technologies Ltd. Logo
AI-powered genomic analysis software to accelerate and optimize plant and animal breeding.
Israel NRGN

Talk to a Data Expert

Have a question? We'll get back to you promptly.